Allogene Therapeutics, Inc. (NASDAQ:ALLO) will be hosting a conference call at 8:30 AM eastern time on 4th November 2020, to discuss its 3Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.allogene.com
Earnings Expectation
Allogene Therapeutics, Inc. is reporting third quarter financial results on Wednesday 4th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, ALLO is expected to report 3Q20 loss of $ 0.54 per share. For the full year, analysts anticipate loss of $ 2.16 per share bottom line.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent.
